Avalo Therapeutics, INC

Avalo Therapeutics announced its second quarter 2026 financial results, detailing progress in its Phase 3 program for abdakibart and expansion with AVTX-010, supported by a robust cash reserve extending into 2029.

Avalo Therapeutics announces the advancement of AVTX-010, a long-acting anti-IL-1 antibody, with an IND submission planned for the first half of 2027.

Avalo Therapeutics executed a preferred stock exchange and amended executive employment agreements regarding change-in-control provisions.

Avalo Therapeutics held its 2026 annual meeting, with stockholders approving amendments to its Employee Stock Purchase Plan and ratifying the appointment of its independent auditor.

Avalo Therapeutics announced positive Phase 2 results for abdakibart in hidradenitis suppurativa and secured $431.3 million in financing, positioning it for Phase 3 trials.

Avalo Therapeutics announced positive topline results from its Phase 2 LOTUS trial for abdakibart in moderate to severe hidradenitis suppurativa, meeting primary endpoints and demonstrating a favorable safety profile.

Avalo Therapeutics, Inc. announced positive Phase 2 results for abdakibart and a significant equity raise, bolstering its financial position and advancing its lead drug candidate.

Avalo Therapeutics announced positive Phase 2 data for abdakibart in hidradenitis suppurativa and completed a significant follow-on offering, bolstering its financial position.

Avalo Therapeutics reported a net loss of $64.5 million for the nine months ended September 30, 2025, but expects existing cash to fund operations into 2028, driven by progress in its AVTX-009 Phase 2 trial.

Avalo Therapeutics reports increased R&D spend for its lead asset AVTX-009's Phase 2 trial, while extending its cash runway into 2028.

Avalo Therapeutics reports a net loss of $13.1 million for Q1 2025, focusing on the development of AVTX-009 and the progression of the LOTUS trial.

Avalo Therapeutics reports a net income of $0.2 million for the nine months ended September 30, 2024, driven by a significant warrant liability adjustment and a recent $58.1 million capital raise from warrant exercises.

Avalo Therapeutics reported a significant increase in net loss for 2025, driven by higher R&D and administrative expenses, as it progresses its lead drug candidate, abdakibart, towards a critical Phase 2 data readout in Q2 2026.

Avalo Therapeutics advances AVTX-009, an anti-IL-1 monoclonal antibody, through Phase 2 trials while reporting a net loss of $35.1 million for 2024.

Avalo Therapeutics shifts its primary focus to AVTX-009, an anti-IL-1 monoclonal antibody, following a significant capital raise and the acquisition of AlmataBio.

Jennifer Riley, Chief Strategy Officer of Avalo Therapeutics, Inc., sold 2,655 shares of common stock on August 11, 2026 for $19.59 per share.

Mittie Doyle, Chief Medical Officer of Avalo Therapeutics, Inc., sold 679 shares of common stock on August 10, 2026 for $20.00 per share.

Mittie Doyle, Chief Medical Officer of Avalo Therapeutics, Inc., sold 1,000 shares of common stock on July 27, 2026 for $20.00 per share.

Avalo Therapeutics Chief Medical Officer Mittie Doyle executed trades under a pre-arranged Rule 10b5-1 plan, acquiring and disposing of company stock.

Avalo Therapeutics director Philip Ron M acquired stock options, as disclosed in a recent SEC Form 4 filing.

Avalo Therapeutics Director Kevin Robert Lind acquired 1,105 stock options on June 30, 2026, as detailed in a Form 4 filing.

Avalo Therapeutics, Inc. has announced its 2026 Annual Meeting of Stockholders will be held virtually on June 2, 2026, with key proposals including director elections and employee stock plan approval.

AVALO Therapeutics will hold its 2025 Annual Meeting on June 17, 2025, with stockholders voting on director elections, executive compensation, and auditor ratification.

Avalo Therapeutics will hold its 2025 Annual Meeting of Stockholders virtually on June 17, 2025, to vote on director elections, executive compensation, and auditor ratification.

Avalo Therapeutics has scheduled its 2024 Annual Meeting for August 13, 2024, outlining several proposals for stockholder consideration, including the election of directors and approval of stock issuance.

Avalo Therapeutics is holding its annual stockholder meeting on August 13, 2024, to vote on the election of directors, approval of stock issuances, equity incentive plans, and other important matters.

Avalo Therapeutics has acquired AlmataBio through a merger and secured a $115.6 million private placement to fund the acquisition and advance its clinical programs.

Nantahala Capital Management, LLC, along with its managing members Wilmot B. Harkey and Daniel Mack, has reported beneficial ownership of 1,862,250 shares, representing 3.54% of Avalo Therapeutics, Inc.'s common stock as of June 30, 2026.

Caligan Partners LP and David Johnson have reported beneficial ownership of 5.9% of Avalo Therapeutics, Inc. common stock as of June 30, 2026.

RA Capital Management, along with affiliated entities and individuals, has reported beneficial ownership of 3,483,099 shares, representing 6.3% of Avalo Therapeutics, Inc.'s common stock.

Avoro Capital Advisors LLC and Behzad Aghazadeh report beneficial ownership of 4.44% of Avalo Therapeutics, Inc. common stock.

Deep Track Capital, LP, along with its affiliates, has reported beneficial ownership of 3,610,000 shares, representing 6.87% of Avalo Therapeutics, Inc. common stock.

FMR LLC and Abigail P. Johnson have updated their Schedule 13G filing, reporting beneficial ownership of 10.8% of Avalo Therapeutics Inc.'s common stock as of July 31, 2026.